

CURRICULUM VITAE

DINESH ARAB, M.D., F.A.C.C., F.S.C.A.I.

PROFESSIONAL EXPERIENCE

- 1/1/2016 – Present Chairman, Clinically Integrated Network
Florida Care Network
Florida Hospital Memorial Medical Center
301 Memorial Medical Parkway
Daytona Beach, FL 32117
- 3/1/2016- Present Director Structural Heart Program
Florida Hospital Memorial Medical Center
301 Memorial Medical Parkway
Daytona Beach, FL 32117
- 1/1/2013- Present Chairman of Medicine
Florida Hospital Memorial Medical Center
301 Memorial Medical Parkway
Daytona Beach, FL 32114
- 10/1/09- 02/29/2016 Director of Cardiology
Florida Hospital Memorial Medical Center
301 Memorial Medical Parkway
Daytona Beach, FL 32117
- 11/15/2010- Present Clinical Assistant Professor of Cardiology
The Florida State University, College of Medicine
Daytona Beach Regional Campus
1200 W. International Speedway Boulevard,
Building 600, Suite 101
Daytona Beach, FL 32114
- 10/1/10- 2/29/2016 Director of Chest Pain Center
Florida Hospital Memorial Medical Center
301 Memorial Medical Parkway
Daytona Beach, FL 32117
- 1/1/10-2/29/2016 Director, Carotid Stent Program.
Florida Hospital Memorial Medical Center

301 Memorial Medical Parkway
Daytona Beach, FL 32117

7/1/06- Present
Cardiology Physicians, P.A.
305 Memorial Medical Parkway, Suite 301
Daytona Beach, FL, 32117
Telephone: 386-671-0691

7/1/06-Present
Cardiology Associates Research Company
305 Memorial Medical Parkway, Suite 301
Daytona Beach, FL 32117
Telephone: 386-677-6672 Fax: 386-677-0541

1/1/05 – 4/30/06
Assistant Professor of Medicine
Loyola University Medical Center
2160 S. First Avenue
Maywood, IL 60153

COMMITTEES

1/1/2011- Present
Medical Executive Committee
Florida Hospital Memorial Medical Center
301 Memorial Medical Parkway
Daytona Beach, FL 32117

1/1/2011- Present
Medical Information Committee
Florida Hospital Memorial Medical Center
301 Memorial Medical Parkway
Daytona Beach, FL 32117

6/10/2010- Present
Chairman, Acute MI Committee
Halifax Health Medical Center
303 N. Clyde Morris Blvd.
Daytona Beach, FL 32114

6/2010- Present
PEER Review Committee
Florida Hospital Memorial Medical Center
301 Memorial Medical Parkway
Daytona Beach, FL 32117

06/08- Present
Physician Leadership Committee

Florida Hospital Memorial Medical Center
301 Memorial Medical Parkway
Daytona Beach, FL 32117

EDUCATION

7/2003-12/05 Interventional Cardiology Fellowship, Loyola University
Medical Center, Chicago, IL.
Peripheral: Trained in Endovascular Peripheral Procedures
including Laser Artherectomy. (CSI, Silverhawk)

6/2000-6/2003 Fellowship in Cardiovascular Disease, SUNY at Buffalo,
NY.

6/1997-6/2000 Residency in Internal Medicine, SUNY at Buffalo, NY

6/1989-6/1995 **M.B.B.S.** (Bachelor of Medicine and Bachelor of
Surgery). Mahadevappa Rampure Medical College,
Gulbarga, Karnataka, India.

COURSE PROCTER AND COMPANY AFFILIATION

CORDIS Endovascular Course Procter 1/09- Present

CSI Atherectomy Course Procter 06/08- Present

BARD Procter Endovascular 06/09- Present

HOSPITAL AFFILIATIONS

07/01/2006-Present: Interventional Cardiologist on staff
Florida Hospital Memorial Medical Center, Daytona
Beach, FL

07/01/2006-Present: Interventional Cardiologist on staff
Halifax Hospital, Daytona Beach, FL

CLINICAL EXPERIENCE

1/1/05-3/01/2007 **Assistant Professor in Medicine**, Loyola University
Medical Center.

- 7/1/2003 – 1/1/05 **Fellowship in Interventional Cardiology**, Loyola University, Chicago, IL. Performed over 300 coronary interventions. Proficient in rotablation and complex angioplasty. Six months of training in peripheral angiography and intervention.
- 6/18/2000- 6/20/2003 **Fellowship in Cardiology**, State University of New York at Buffalo Medical- Dental Education consortium, Buffalo, NY.
- 6/18/1999- 6/18/2000 **Chief Resident, Department of Medicine**, University at Buffalo, VA Hospital, Buffalo, NY.
- 6/1997- 6/18/2000 **Residency in internal medicine**, State University of New York (SUNY) at Buffalo Medical- Dental Education consortium, Buffalo, New York.
- 8/1996-1/1997 **Senior House Officer**, Emergency Medicine, Bassetlaw General Hospital, Nottinghamshire, UK.
- 5/1995-5/1996 **Rotating Internship**, Osmania General Hospital, Hyderabad, India.

TEACHING EXPERIENCE

- 1997- 2003 **Clinical Assistant Instructor of Internal Medicine, SUNY at Buffalo**, Buffalo, NY.
- 6/1999-6/2000 **Chief Resident, Department of Medicine, University at Buffalo.**

ACADEMIC ACHIEVEMENTS

- 2000 **Siegel Award, for teaching excellence**, presented by the student body committee, SUNY at Buffalo.
- 1999 **Certificate of Merit, American College of Physicians**, for research poster finals, National ACP Meeting, New Orleans. Analysis of the QT Segment Duration in Exercise Stress Testing As a Predictor of Ischemia.
- 1999 **Certificate of Merit, American College of Physicians, New York Chapter**, for research poster finals, ACP Upstate Poster Competition. Natural History of Pulmonary

Artery Pressures in Patients Awaiting Cardiac Transplantation.

- 1998 **Dr. Norman Chassin Award, for outstanding Intern of the Year.**
- 1996 **PLAB EXAM**, Professional and Linguistic Assessment Board Examination conducted by the General Medical Council, United Kingdom.
- 1995 **Certificate of Merit**, by the Indian Academy of Pediatrics.
- 1995 **First Division (Honors) in all three Phases of Medical School.**
- 1994 **Honors in Internal Medicine**
- 1992 **Honors in Pharmacology**
- 1992 **Honors in Microbiology**
- 1989 **Honors in Physiology**

Publications

- 2011 Co-author of Abstract, "Results of the Confirm II Study Demonstrating the Value of Orbital Technology Effectively Restoring Flow in Patients with Calcified Intra-inguinal Disease" Abstract presented at TCT 2011
- 2007 D. Joyal, R. Ramana, D. Arab, Troponin Levels in PreEclampsia. Journal of American Medicine: In Press
- 2006 J. Freihage, D. Joyal, D. Arab, R. Dieter, et al. Invasive assessment of mitral regurgitation: Comparison of hemodynamic parameters. Catheterization and Cardiovascular Interventions; Dec 2006.
- 2005 Arab D, Leya F, Cho L, et al. Guidelines for Antiplatelet Therapy in Anticoagulated Patients Requiring Coronary Intervention. Journal of Invasive Cardiology: In Press.

- 2005 Leya F, Arab D, Joyal D, et al. The Efficacy of Brain Natriuretic Peptide Levels in Differentiating Constrictive Pericarditis from Restrictive Cardiomyopathy. JACC: In Press.
- 2003 Arab D, Kirmani JF, Xavier AR, Yahia AM, Qureshi AI. Cardiac Monitoring in the Neurological Intensive Care Unit. In Suarez JI (ed). Critical Care Neurology and Neurosurgery. Totowa, New Jersey: Humana Press, 2003, 137-150.
- 2003 Arab D. Yahia AM. Qureshi AI. Cardiovascular manifestations of acute intracranial lesions: pathophysiology, manifestations, and treatment. Journal of Intensive Care Medicine. 18(3):119-29, 2003 May-Jun.
- 2003 Arab D. Yahia AM. Qureshi AI. Use of intravenous abciximab as adjunctive therapy for carotid angioplasty and stent placement. International Journal of Cardiovascular Interventions. 5(2):61-6, 2003.
- 2000 Arab Dinesh MD, Valeti Venkata MD, Schuneman Holger J MD, Lopez-Candales Angel MD. Usefulness of the QTc Interval in Predicting Myocardial Ischemia in Patients Undergoing Stress Testing. American Journal of Cardiology. 2000;85(6): 764-766.
- 1999 Arab Dinesh MD, Valeti Venkata MD, Lopez-Candales Angel MD, Graham Susan MD. Natural History of Pulmonary Artery Pressure in Patients Awaiting Cardiac Transplantation. Abstract: Journal of Heart Failure, Sep 1999, Supplement.
- 1999 Valeti V, Arab D, Lopez-Candales A. Slow heart rate recovery as a predictor of ischemia during exercise testing in elderly males. Abstract: The American Journal of Geriatric Cardiology, 1999;8(2):95

CLINICAL TRIAL EXPERIENCE

STEM CELLS

2013 NOGA/MYOSTAR CERTIFIED - Electromechanical Guidance for Catheter Based Transendocardial Injection

Sub Investigator for Baxter to determine the efficacy and safety of targeted intramyocardial delivery of G-CSF mobilized autologous CD34+ cells for the improvement in total exercise time during standardized exercise testing in subjects with refractory angina pectoris and chronic myocardial ischemia (RENEW)

Sub Investigator for Aastrom to evaluate the efficacy, safety, and tolerability of transendocardial injection of ixmyelocel-T in subjects with heart failure due to ischemic dilated cardiomyopathy

DEVICE

Principle Investigator for Cardiovascular Systems Inc. in a Pivotal Trial to Evaluate the Safety and Efficacy (Performance) of the Diamondback 360 Orbital Artherectomy System in treating De Novo, Severely Calcified Coronary Lesions (ORBIT II)

Sub Investigator for Tryton Medical to evaluate the Safety and Effectiveness of the Tryton side branch stent used in conjunction with a Drug-Eluting Stent compared to side branch Balloon Angioplasty in conjunction with Drug Eluting Stent in the treatment of de novo Bifurcation Lesions Involving the main branch

CARDIAC GEOMETRY AND FUNCTION

Sub Investigator for Sanofi – Aventis U.S. Inc. in a Placebo Controlled, Double Blind, Randomized, Multicenter study to Assess the Effects of Dronedarone 400mg BID on Cardiac Geometry and Function in Patients with Atrial Fibrillation and Left Atrial Enlargement (HARMONY)

PULMONARY ARTERIAL HYPERTENSION

Principal Investigator for Pfizer in trial of Monotherapy Sitaxentan Sodium versus Combination therapy with Sitaxentan Sodium and Sildenafil Citrate in subjects with Pulmonary Arterial Hypertension

CONGESTIVE HEART FAILURE

Sub Investigator for Pfizer in trial of effect of Eplerenon vs Placebo on CV mortality and

HF hospitalization in patients with NYHA Class II Chronic systolic HF. (EMPHASIS)

ACUTE MYOCARDIAL INFARCTION

Sub Investigator for Glaxo Smith Kline in a study to compare the incidence of major adverse cardiovascular events in pts taking Losmopimod compared to Placebo

Sub Investigator for Astra Zeneca in a randomized clinical trial (PLATO) a study of PLATelet inhibition and patient outcomes.

ACUTE CORONARY SYNDROME

Sub Investigator for Schering Plough in trial to evaluate safety and efficacy of SCH530348 in addition to standard care in patients with ACD (TRACER)

Sub Investigator for Schering Plough in trial of Benefit and Safety of Vytorin vs Simvastatin monotherapy in high risk subjects presenting with ACS (IMPROVE IT)

Sub Investigator for Roche Pharmaceuticals in a clinical trial for treatment of patients post acute coronary syndrome (2nd SYMPHONY)

Sub Investigator for Hoffman La-Roche, a Phase III, double-blind, randomized placebo controlled study, to evaluate the effects of dalcetrapib on cardiovascular risk in stable CHD patients, with a documented recent acute coronary syndrome (ROCHE)

Sub Investigator for Johnson & Johnson, a randomized, double-blind, placebo-controlled, event-driven multicenter study to evaluate the efficacy and safety of Rivaroxaban in subjects with a recent acute coronary syndrome. (TIMI 51)

Sub Investigator for Eli Lilly, a comparison of Prasugrel and Clopidogrel in acute coronary syndrome subjects with unstable angina/non-ST-elevation Myocardial Infarction who are medically managed (TRILOGY)

Sub Investigator for GlaxoSmithKline in a Clinical Outcome Study of Darapladib versus Placebo in Subjects following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (TIMI52)

ISCHEMIA/STABLE ANGINA

Sub Investigator for Momenta in trial to evaluate safety and efficacy of M118 in PCI in patients with stable CAD (EMMINENCE)

Sub Investigator for Schering Plough in trial to evaluate safety and efficacy of SCH530348 in addition to standard care in patients with atherosclerotic disease, (TIMI

50)

Investigator for Gilead Sciences for study of the effects of Ranolazine on major adverse cardiovascular events in subjects with a history of chronic angina who undergo PCI intervention with incomplete revascularization (RIVER PCI)

Sub Investigator for Tasy to confirm the anti-anginal effect of T89 in patients with stable angina

ANTICOAGULANT

Sub Investigator for Boehringer Ingelheim in a Randomized Evaluation of Long Term Anticoagulant Therapy comparing the efficacy and safety of two blinded doses of Dabigatran Etxilate with Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Prospective, Multi-Centre, Parallel-Group, Non Inferiority Trial (RELY)

Sub Investigator for Daiichi Sankyo, a Phase III, randomized, double-blind, double-dummy, parallel group, multi-optional study for the evaluation of efficacy and safety of DU-176b vs Warfarin in subjects with A-Fib with Factor Xa next generation in A-Fib (ENGAGE)

Sub Investigator for Merck, a Phase II, open label, dose exposure confirmation study to Evaluate the Pharmacokinetics and Safety and Tolerability of Betrixaban (MK-4448) in adult patients with Non-Valvular Artial Fibrillation or Atrial Flutter (MK-4448)

ANTI-PLATLET AGGREGATION

Sub Investigator for Astra Zeneca AB in a Randomized, Double-Blind, Placebo controlled, Parallel Group, Multi-national Trial, to assess the Prevention of Thrombotic Events with Ticagrelor compared to Placebo on a background of ASA therapy in patients with a history of Myocardial Infarction (Pegasus – TIMI 54)

PCI

Sub Investigator for Schering-Plough in a multi-center randomized, double blind, placebo controlled study to evaluate the safety of SCH530348 in subjects undergoing non-urgent Percutaneous Coronary Intervention (TRA)

Sub Investigator for Cordis Corp. in a “Prospective, Randomized, Multi-Center, Double-Blind Trial to Assess the effectiveness and Safety of Different Durations of Dual Anti-platelet Therapy (DAPT) in Subjects undergoing eluting Coronary Stent

(CYPHER)

Sub Investigator for Regado Biosciences to determine the efficacy and safety of the REG1 anti-coagulation system compared to Bivalirudin

METABOLIC SYNDROME

Sub Investigator for Sanofi Aventis in a study of Rimonabant for reducing the risk of major CV events in abdominally obese patients with clustering of risk factors (CRESCENDO)

Sub Investigator for Eisai to evaluate long term treatment with BELVIQ on the incidence of major adverse cardiovascular events and conversion to DMII in Obese and overweight subjects with CVD or multiple risk factors CV risk factors

DIABETES

Sub Investigator for Astra Zeneca in a Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV trial to evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in patients with Type II Diabetes (SAVOR)

Sub Investigator for Astra Zeneca to evaluate the effect of Dapagliflozin 10mg on the incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in patients with Type II Diabetes (Declare)

PERIPHERAL ARTERY DISEASE

Sub Investigator for Astra Zeneca comparing Ticagrelor with Clopidogrel treatment on the risk of Cardiovascular death, Myocardial Infarction and Ischemic Stroke in patients with established PAD

ATRIAL FIBRILLATION

Sub Investigator for Daiichi Sankyo comparing Edoxaban vs Warfarin in subjects undergoing Cardioversion of Atrial Fibrillation

Sub Investigator for Bayer Healthcare Pharmaceuticals exploring the efficacy and safety of once daily Rivaroxaban compared to VKA for the prevention of Cardiovascular events

in subjects with nonvalvular atrial fibrillation scheduled for cardioversion.

Sub Investigator for Sanofi-Aventis, a randomized, double-blind, placebo controlled, parallel group trial for assessing the clinical benefit of Dronedarone 40MG bid on top of standard therapy in patients with permanent Atrial Fibrillation and additional factors (PALLAS)

Sub Investigator in a Phase IIIb randomized, double-blind, placebo controlled, parallel group trial to evaluate the safety and efficacy of Vernakalant Hydrochloride injection in patients with recent onset symptomatic Atrial Fibrillation (ASTELLAS)

HYPERLIPIDEMIA

Sub Investigator for Amgen in a Double Blind, Randomized, Placebo –Controlled, Multicenter, Dose ranging study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in combination with HMG-CoA Reductase Inhibitors in Hypercholesterolemic Subjects (AMGEN – TIMI 57)

Sub Investigator for the University of Oxford in a (Randomized Evaluation of the Effects of Anacetrapib through Lipid Modification): A large scale, randomized, placebo controlled trial of the clinical effects of Anacetrapib among people with established vascular disease (REVEAL)

Sub Investigator for Sanofi - long term safety and tolerability of REGN/SAR236553 in high CV risk patients with Hypercholesterolemia not adequately controlled with their LMT.

Sub Investigator for Sanofi to evaluate the effect of SAR236553/REGN727 on the occurrence of cardiovascular events in patients who have recent ACS (ODYSSEY OUTCOMES)

Sub Investigator for Amgen to evaluate the safety, tolerability and efficacy of AMG145 on LDL-C in combination with statin therapy in subjects with primary hypercholesterolemia and mixed dyslipidemia (Laplace-2)

Sub Investigator for Amgen assessing the impact of Additional LDL Cholesterol reduction on major cardiovascular events when AMG145 is used in combination with statin therapy in patients with clinically evident cardiovascular disease (Fourier)

VENOUS THROMBO-EMBOLISM

Sub Investigator for Janssen in Medically Ill patient assessment of Rivaroxaban Versus Placebo in Reducing Post Discharge VTE risk (Mariner)

PROFESSIONAL AFFILIATIONS

American College of Physicians
American College of Cardiology
The Society of Cardiac Angiography and Interventions

CERTIFICATIONS

Board Certified in Interventional Cardiology (2004).
Board Certified in Cardiology (2003)